TRCT
PMVP icon

Tower Research Capital (TRC)’s PMV Pharmaceuticals PMVP Stock Holding History

Tower Research Capital (TRC)’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.69K Sell
1,365
-2,540
-65% -$3.23K ﹤0.01% 4613
2025
Q4 		$4.88K Buy
+3,905
New +$5.23K ﹤0.01% 4171
2025
Q3 		– Sell
-3,688
Closed -$3.91K – 5529
2025
Q2 		$3.91K Buy
3,688
+2,968
+412% +$2.91K ﹤0.01% 4412
2025
Q1 		$785 Sell
720
-805
-53% -$1.09K ﹤0.01% 4831
2024
Q4 		$2.3K Sell
1,525
-662
-30% -$1.05K ﹤0.01% 4866
2024
Q3 		$3.26K Sell
2,187
-12,709
-85% -$19.6K ﹤0.01% 4874
2024
Q2 		$24.1K Buy
14,896
+10,250
+221% +$18.5K ﹤0.01% 3653
2024
Q1 		$7.9K Sell
4,646
-4,862
-51% -$9.08K ﹤0.01% 4117
2023
Q4 		$29.5K Buy
9,508
+7,368
+344% +$19.5K ﹤0.01% 3436
2023
Q3 		$13.1K Buy
2,140
+1,165
+119% +$8.01K ﹤0.01% 3825
2023
Q2 		$6.1K Sell
975
-813
-45% -$4.26K ﹤0.01% 4739
2023
Q1 		$9K Sell
1,788
-10,304
-85% -$72.5K ﹤0.01% 4528
2022
Q4 		$105K Sell
12,092
-12,602
-51% -$134K ﹤0.01% 1801
2022
Q3 		$294K Buy
24,694
+10,592
+75% +$153K ﹤0.01% 1568
2022
Q2 		$201K Buy
14,102
+13,017
+1,200% +$189K ﹤0.01% 1770
2022
Q1 		$23K Sell
1,085
-8,595
-89% -$152K ﹤0.01% 3400
2021
Q4 		$224K Buy
9,680
+6,142
+174% +$148K ﹤0.01% 1673
2021
Q3 		$105K Buy
3,538
+2,503
+242% +$79.9K ﹤0.01% 2361
2021
Q2 		$35K Sell
1,035
-1,737
-63% -$58K ﹤0.01% 3329
2021
Q1 		$91K Buy
2,772
+2,333
+531% +$92K ﹤0.01% 2659
2020
Q4 		$27K Buy
+439
New +$17.2K ﹤0.01% 3665

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Tower Research Capital (TRC)'s PMVP Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its PMV Pharmaceuticals (PMVP) stake by 65% in Q1 2026, selling an estimated $3.23K and leaving 1,365 shares worth $1.69K. The position accounts for ﹤0.01% of the portfolio, ranked #4613.

Tower Research Capital (TRC) first reported a position in PMVP in Q4 2020 and has held it in 21 quarters since. The position peaked at $294K in Q3 2022. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.

  • Tower Research Capital (TRC) held 1,365 shares of PMV Pharmaceuticals worth $1.69K as of Q1 2026.
  • Tower Research Capital (TRC) sold 2,540 PMV Pharmaceuticals shares in Q1 2026, an estimated $3.23K.
  • PMV Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4613 holding.
  • Tower Research Capital (TRC) first reported a position in PMV Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s PMV Pharmaceuticals position peaked at $294K in Q3 2022.
  • 69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.